After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Relmada Therapeutics Q2 Earnings Call Highlights
Relmada Therapeutics NASDAQ: RLMD said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, as it targets an investigational new drug application filing by the end of 2026.
Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript
Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript
Relmada Therapeutics Q1 Earnings Call Highlights
Relmada Therapeutics NASDAQ: RLMD said it remains on track to begin its Phase 3 RESCUE registrational program for NDV-01 in mid-2026 after reporting 12-month Phase 2 data in non-muscle invasive bladder cancer and strengthening its balance sheet through a private financing.
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 75.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 92.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
RLMD Stock Surges 42% in a Week: Here's What You Should Know
Relmada Therapeutics jumps 42% in a week after reporting encouraging efficacy and safety data from a mid-stage bladder cancer study of NDV-01, simultaneously sharing phase III plans.
Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript
Relmada Therapeutics, Inc. ( RLMD ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Sergio Traversa - CEO & Director Raj Pruthi - Chief Medical Officer of Urology Maged Shenouda - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Uy Ear - Mizuho Securities USA LLC, Research Division Presentation Operator Good afternoon, and welcome to Relmada Therapeutics Third Quarter 202 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for replay on the Relmada website.
Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Maged S. Shenouda - Chief Financial Officer Raj S.
